An emotional rescue for America came via the first U.S. artificial satellite. Explorer 1 was boosted into space by the Army ...

The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell ...

Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events were slightly higher in nivolumab plus ...

Real world data show that immunotherapy leads to better overall survival outcomes than chemotherapy in patients with ...

Early clinical results suggest the firm's antibodies targeting the Vβ T-cell receptor could induce strong and durable responses in cancer patients.

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Durable complete response (CR) in a MCC patient treated with 15 mg/kg solnerstotug + cemiplimab. Patient continues on ...

A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable ...

A major scientific leap has been made with the creation of the longest ultra-secure quantum satellite link between China and ...

The safety and efficacy of dostarlimab plus chemotherapy in patients with advanced endometrial cancer were confirmed by ...

The firm says it has a path forward for a Phase II/III registration-enabling study of NOUS-209 after positive meetings with the FDA.

Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ...